Overweight and obesity are highly prevalent drivers of serious and costly chronic diseases, resulting in 5 million premature deaths annually and projected to increase 40% by 2030. There is an increasing realization that treatment can change the trajectory of major prevalent chronic diseases and generate substantial economic growth as worldwide adoption and market growth accelerate. Using its proprietary Half-life Augmentation by Lipid Optimization, or HALO, and MOMENTUM oral NuSH analog peptide delivery platforms, Metsera is developing a broad portfolio of wholly owned, novel, combinable, ultra-long-acting (ULA) injectable and oral NuSH analog peptides designed to drive significant benefits for patients and consumers living with overweight and obesity.